If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
== Further reading == Iwata TN, Sugihara K, Wada T, Agatsuma T (October 2019). "[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model". PLOS ONE. 14 (10) e0222280. Bibcode:2019PLoSO..1422280I. doi:10.1371/journal.pone.0222280. PMC 6772042. PMID 31574081.{{cite journal}}: CS1 maint: overridden setting (link) Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. (February 2020). "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer". N. Engl. J. Med. 382 (7): 610–621. doi:10.1056/NEJMoa1914510. PMC 7458671. PMID 31825192.{{cite journal}}: CS1 maint: overridden setting (link)
The enzymatic steps involved in the elongation process are principally the same as those carried out by fatty acid synthesis, but the four principal successive steps of the elongation are performed by individual proteins, which may be physically associated.
Between 2012 and 2017, the birth rate was 14.3 per thousand and the mortality rate was 10.4 per thousand: even though the Rate of natural increase is positive it does not compensate for the clearly negative net migration rate (-0.7%). In 2017 19% of Le Havre's population was under 15 years old and 39% were under 30 years old, which was above the average for metropolitan France. 24% of men and 26% of women were over 60 years old. The most populous quarters are the city centre, Sanvic, Caucriauville, Anatole France/Danton and Côte Ouest/Ormeaux. In 2009 the foreign population was estimated at 8,525 persons or 4.8% of the population. 12,148 immigrants lived in Havre, or 6.8% of the urban population. Most had North African (5060) or African (3114) origins. With the economic changes that have affected the city, the Professions and Socio-professional categories (PCS) have changed dramatically since the 1980s: between 1982 and 1999, the number of workers has declined by about a third (−10,593), their share of the active labour force was 16% in 1982 and 12.5% in 1999. The population of workers is concentrated in the southern suburbs close to the port and the industrial zone. At the same time the numbers of executives and intellectual professions increased by 24.5%, which is explained in part by the creation and development of the University of Le Havre. In 2017 the city had a lower proportion of managers and intellectual occupations than the national average (14.4% against 18.1%). The proportion of workers (22.5%) was higher than the national average (19.9%).
=== Dynamics === Both experimental evidence and mathematical modeling indicate that p53 levels oscillate over time in response to cellular signals. These oscillations become more pronounced in the presence of DNA damage, such as double-stranded breaks or UV exposure. Modeling approaches also help illustrate how mutations in p53 isoforms affect oscillatory behavior, potentially informing tissue-specific therapeutic development.
Sources: en.wikipedia.org
Four people were killed and twelve others were injured in overnight Russian drone strikes on Kharkiv. Another person was killed in a separate attack outside the city. Two people were killed in an airstrike in New York, Donetsk Oblast. The Institute for the Study of War (ISW) assessed that Russian forces had reached the eastern suburbs of Chasiv Yar but were held back by Ukrainian forces. Russia claimed to have shot down 13 drones over Belgorod, Kursk and Tula Oblasts. Ukraine gave certificates of gratitude to a multinational group of "vigilante hackers" known as One Fist responsible for launching cyberattacks on Russian military firms and CCTV cameras "dozens of times". The FSB announced the capture of a former Israeli Defence Force soldier who was trying to join the Ukrainian army. He was given a formal warning and deported back to Israel. A Ukrainian court sentenced a suspect in the 2023 Kramatorsk restaurant missile strike to life imprisonment for aiding Russian forces in the attack. Moldovan Border Police found the wreckage of a Russian drone near Etulia, at about 500 metres (1,600 feet) from the Moldova–Ukraine border.
(February 2, 2016), "Forensic Chemistry and Ambient Mass Spectrometry: A Perfect Couple Destined for a Happy Marriage?", Analytical Chemistry, 88 (5), American Chemical Society (ACS): 2515–2526, doi:10.1021/acs.analchem.5b02397, ISSN 0003-2700, PMID 26768158 Wu, Chunping; Dill, Allison L.; Eberlin, Livia S.; Cooks, R. Graham; Ifa, Demian R. (September 20, 2012), "Mass spectrometry imaging under ambient conditions", Mass Spectrometry Reviews, 32 (3), Wiley: 218–243, doi:10.1002/mas.21360, ISSN 0277-7037, PMC 3530640, PMID 22996621 Eberlin, Livia S.; Norton, Isaiah; Orringer, Daniel; Dunn, Ian F.; Liu, Xiaohui; Ide, Jennifer L.; Jarmusch, Alan K.; Ligon, Keith L.; Jolesz, Ferenc A.; Golby, Alexandra J.; Santagata, Sandro; Agar, Nathalie Y. R.; Cooks, R. Graham (January 8, 2013), "Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors", Proceedings of the National Academy of Sciences, 110 (5): 1611–1616, Bibcode:2013PNAS..110.1611E, doi:10.1073/pnas.1215687110, ISSN 0027-8424, PMC 3562800, PMID 23300285 Eberlin, Livia S.; Norton, Isaiah; Dill, Allison L.; Golby, Alexandra J.; Ligon, Keith L.; Santagata, Sandro; Cooks, R. Graham; Agar, Nathalie Y.R. (January 31, 2012), "Classifying Human Brain Tumors by Lipid Imaging with Mass Spectrometry", Cancer Research, 72 (3), American Association for Cancer Research (AACR): 645–654, doi:10.1158/0008-5472.can-11-2465, ISSN 0008-5472, PMC 3271168, PMID 22139378
As an AAS, ethylestrenol is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and dihydrotestosterone (DHT). It has low estrogenic activity (via aromatization into ethylestradiol following transformation into norethandrolone), strong progestogenic activity, and a high ratio of anabolic to androgenic activity, similarly to other nandrolone derivatives. Like other 17α-alkylated AAS, ethylestrenol has a risk of hepatotoxicity.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.